Page last updated: 2024-09-05

sb 216763 and Cognition Disorders

sb 216763 has been researched along with Cognition Disorders in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Datusalia, AK; Sharma, SS	1

Other Studies

1 other study(ies) available for sb 216763 and Cognition Disorders

Article	Year
Amelioration of diabetes-induced cognitive deficits by GSK-3β inhibition is attributed to modulation of neurotransmitters and neuroinflammation. Molecular neurobiology, 2014, Volume: 50, Issue:2 Topics: Animals; Cognition Disorders; Diabetes Mellitus, Experimental; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hippocampus; Indoles; Inflammation; Male; Maleimides; Neurotransmitter Agents; Nitric Oxide Synthase Type II; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Signal Transduction; Tumor Necrosis Factor-alpha	2014

Article

Year

Amelioration of diabetes-induced cognitive deficits by GSK-3β inhibition is attributed to modulation of neurotransmitters and neuroinflammation.

Molecular neurobiology, 2014, Volume: 50, Issue:2

Topics: Animals; Cognition Disorders; Diabetes Mellitus, Experimental; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hippocampus; Indoles; Inflammation; Male; Maleimides; Neurotransmitter Agents; Nitric Oxide Synthase Type II; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Signal Transduction; Tumor Necrosis Factor-alpha

2014